Irritable Bowel Syndrome News and Research RSS Feed - Irritable Bowel Syndrome News and Research

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine, often causing bouts of cramping, abdominal pain, bloating, diarrhea and constipation.

IBS is not curable but, in most cases, people learn to live with and control the condition by managing diet, lifestyle and stress levels. Medications to treat diarrhea, pain killers or drugs that relieve painful bowel spasms may also be used.

The cause of IBS is not yet clear but it is linked to changes in the way food is moved through the bowel. In healthy people, layers of muscle lining the intestinal wall contract and relax in a coordinated manner to move food from the stomach, through the colon and into the rectum. When an individual has IBS, however, the contractions are unusually strong and food is passed through the intestine too quickly which leads to diarrhea and a build up of gas.

Triggers for IBS range from pressure on the intestines to certain foods such as chocolate or carbonated drinks, hormonal changes such as during the menstrual cycle and emotional changes such as an increase in stress.

IBS can be painful and debilitating if not treated appropriately, negatively impacting on a person’s quality of life. However, with appropriate treatment individuals with IBS should be able to live a full and active life.
10 million of us lack sunshine vitamin

10 million of us lack sunshine vitamin

Health pioneers BetterYou have welcomed the views of Nutritionist Marilyn Glenville, that ‘oil based supplements can help you get your recommended dose of vitamin D’. [More]
Neurons protect intestinal tissue from over-inflammation

Neurons protect intestinal tissue from over-inflammation

The immune system exercises constant vigilance to protect the body from external threats--including what we eat and drink. A careful balancing act plays out as digested food travels through the intestine. Immune cells must remain alert to protect against harmful pathogens like Salmonella, but their activity also needs to be tempered since an overreaction can lead to too much inflammation and permanent tissue damage. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Researchers reveal biological connection between obesity and colorectal cancer risk

Researchers reveal biological connection between obesity and colorectal cancer risk

Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood. Now, a research team led by investigators at Thomas Jefferson University has revealed the biological connection, and in the process, has identified an approved drug that might prevent development of the cancer. [More]
First trials of smart gas sensing pills offer new clues for development of gut disorder treatments

First trials of smart gas sensing pills offer new clues for development of gut disorder treatments

Researchers have conducted the first ever trials of smart pills that can measure intestinal gases inside the body, with surprising results revealing some unexpected ways that fibre affects the gut. [More]
Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. [More]
Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term. [More]
Enteric nerves of irritable bowel syndrome patients respond poorly to inflammatory substances

Enteric nerves of irritable bowel syndrome patients respond poorly to inflammatory substances

For the first time, biopsies of patients with irritable bowel syndrome have shown that the nerves in their gut wall respond poorly to a cocktail of inflammatory substances. This refutes the previous theory that patients with irritable bowel syndrome have an overly sensitive gut. [More]
Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). [More]
Scientists can accurately measure microbial growth rates inside gastrointestinal tracts

Scientists can accurately measure microbial growth rates inside gastrointestinal tracts

For the first time, scientists can accurately measure population growth rates of the microbes that live inside mammalian gastrointestinal tracts, according to a new method reported in Nature Communications by a team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School. [More]
Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition. [More]
Loyola gastroenterologist provides tips to IBS patients for healthy living

Loyola gastroenterologist provides tips to IBS patients for healthy living

More than 20 percent of the US population lives with irritable bowel syndrome (IBS) and for many Americans it is an ongoing challenge. But when it comes to treatment, old advice from Mom was right. Often, the key is to eat right and go outside and play. [More]
Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Laboratories, LLC ("Commonwealth") announced today that it has formed an agreement with Quest Diagnostics ("Quest") that will expand the availability of IBSchek™, a new laboratory developed blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS). [More]
Study evaluates effectiveness of hypnotherapy

Study evaluates effectiveness of hypnotherapy

Although hypnosis has existed for hundreds of years, today it is still difficult to clearly judge its usefulness in the medical domain. [More]
GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

The protein glycomacropeptide (GMP) is derived from whey, the liquid by-product of the cheese-making process. GMP contains low amounts of the amino acid phenylalanine. Individuals who suffer from phenylketonuria—a metabolic disorder that causes cognitive impairment when phenylalanine level is too high—can use GMP as an alternative protein source. GMP supplementation has also been observed to improve gastrointestinal health by protecting the digestive system from pathogens and by having an anti-inflammatory effect. [More]
Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015. [More]
Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. [More]
Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Researchers at Sheffield Teaching Hospitals have received awards for their work investigating coeliac disease and irritable bowel syndrome, two common gastrointestinal conditions. [More]
Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information. [More]
SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

The relationship between mental and physical health is well established. But when mental and physical illnesses co-occur, patients' accounts of physical illness are sometimes arbitrarily discredited or dismissed by physicians. [More]
Advertisement